Otsuka showcases kidney drug data; Pfizer cuts an AI deal

An article from

News roundup

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends.

Published June 4, 2026

Getty Images

Otsuka showcases kidney drug data; Pfizer cuts an AI deal

Other newsrooms on this story

Related reading

In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline…

Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection

Otsuka touts new IgAN evidence as it seeks full approval for Voyxact

Otsuka reports long-term kidney data key to Voyxact's bid for full approval

Vera's IgAN approval kicks off competition with Otsuka

FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with…